Cansino Biotech announced that the adsorbed tetanus vaccine developed by the company has been approved by the China National Drug Administration for marketing as a new drug. The vaccine is fermented using animal-free media and is mainly used to prevent non-neonatal tetanus. Phase III clinical data showed that GMC antibodies were superior to the control vaccine 30 days after exemption, and had obvious immunogenic advantages. The company has reached an exclusive commercialization cooperation agreement with Yuanda Life Sciences Group for this vaccine.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.